Author | Gerald S. Falchook, MD | OncLive

Author | Gerald S. Falchook, MD

Articles

Dr. Falchook on TRK Alterations in Lung Cancer

August 13, 2018

Video

Gerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses TRK alterations in lung cancer.

Dr. Falchook on KTN3379 in Advanced Tumors

July 29, 2016

Video

Gerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses a phase Ib study examining the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the anti-ErbB3 agent KTN3379 in adults with advanced tumors. The agent was studied alone and with targeted therapies.

x